selexipag
Sign in to saveSelexipag, sold under the brand name Uptravi, is a medication developed by Actelion for the treatment of pulmonary arterial hypertension (PAH). Selexipag and its active metabolite, ACT-333679 (or MRE-269, the free carboxylic acid), are agonists of the prostacyclin receptor, which leads to vasodilation in the pulmonary circulation. It is taken by mouth or administered intravenously.
Key facts
- Drug.Verifiedfields
- changed
- Drug.verifiedrevid
- 444391072
- Drug.image
- Selexipag.svg
- Drug.image_class
- skin-invert-image
- Drug.tradename
- Uptravi
- Drug.DailyMedID
- Selexipag
- Drug.routes_of_administration
- By mouth, intravenous
- Drug.class
- prostacyclin receptor agonist
- Drug.ATC_prefix
- B01
- Drug.ATC_suffix
- AC27
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.bioavailability
- 49%
- Drug.protein_bound
- 99%
- Drug.metabolism
- Activation by carboxylesterases, inactivation by CYP2C8 and others
- Drug.metabolites
- ACT-333679, the free acid (active metabolite)
via Wikipedia infobox
Article
13 sectionsContents
- Medical uses
- Contraindications
- Adverse effects
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- Chemistry
- Synthesis
- History
- Society and culture
- Economics
- References
- External links
{{Infobox drug | Verifiedfields = changed | verifiedrevid = 444391072 | image = Selexipag.svg | image_class = skin-invert-image | width = | alt = | caption =
| pronounce = | tradename = Uptravi | Drugs.com = | MedlinePlus = | DailyMedID = Selexipag | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_category= | routes_of_administration = By mouth, intravenous | class = prostacyclin receptor agonist | ATC_prefix = B01 | ATC_suffix = AC27 | ATC_supplemental =